Advertisement

Lifestyle and Dietary Factors in Prostate Cancer Prevention

  • Andrea Discacciati
  • Alicja WolkEmail author
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 202)

Abstract

The etiology of prostate cancer (PCa) is still largely unknown and the only well-established risk factors are those that are non-modifiable (age, race, and family history). Therefore, the identification of lifestyle and dietary factors which might prevent PCa development and progression is of paramount importance from a public health point of view. Accumulating evidence indicates that obesity may have a dual effect on PCa: an increased risk of aggressive PCa and a decreased risk of localized PCa. Both occupational and leisure time physical activity have been observed to be associated with a reduced PCa risk. Different dietary factors including coffee have been examined in several epidemiological studies, but results have been mostly inconsistent. However, these inconsistencies can be, at least partly, explained by the fact that the majority of those studies examined total PCa risk only and, in addition, they did not take into account the different genetic characteristics within the study populations. Therefore, the future epidemiological studies should focus on the analysis of PCa subtypes separately in order to examine possible etiological heterogeneity of PCa in relation to some exposures. In addition, differences in the genetic characteristics of the study participants should be taken into account to explore the possibility of gene–environment interactions.

Keywords

Leisure Time Physical Activity Dietary Factor Coffee Consumption Recreational Physical Activity Modifiable Lifestyle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Allott EH, Masko EM, Freedland SJ (2013) Obesity and prostate cancer: weighing the evidence. Eur Urol 63(5):800–809. doi: 10.1016/j.eururo.2012.11.013, S0302-2838(12)01344-9 [pii]PubMedCrossRefGoogle Scholar
  2. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J, Higgins B, Lynch S, Rozanski T, Troyer D, Thompson I (2005) The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103(5):1092–1095. doi: 10.1002/cncr.20856 PubMedCrossRefGoogle Scholar
  3. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ (2007) Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298(19):2275–2280. doi: 10.1001/jama.298.19.2275, 298/19/2275 [pii]PubMedCrossRefGoogle Scholar
  4. Chu DI, De Nunzio C, Gerber L, Thomas JA 2nd, Calloway EE, Albisinni S, Senocak C, McKeever MG, Moreira DM, Tubaro A, Moul JW, Freedland SJ, Banez LL (2011) Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. Prostate Cancer Prostatic Dis 14(4):346–353. doi: 10.1038/pcan.2011.31, pcan201131 [pii]PubMedCrossRefGoogle Scholar
  5. Discacciati A, Orsini N, Andersson SO, Andren O, Johansson JE, Mantzoros CS, Wolk A (2013) Coffee consumption and risk of localized, advanced and fatal prostate cancer: a population-based prospective study. Ann Oncol. doi: 10.1093/annonc/mdt105, mdt105 [pii]Google Scholar
  6. Discacciati A, Orsini N, Andersson SO, Andren O, Johansson JE, Wolk A (2011) Body mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study. Br J Cancer 105(7):1061–1068. doi: 10.1038/bjc.2011.319, bjc2011319 [pii]PubMedCentralPubMedCrossRefGoogle Scholar
  7. Discacciati A, Orsini N, Wolk A (2012) Body mass index and incidence of localized and advanced prostate cancer–a dose-response meta-analysis of prospective studies. Ann Oncol 23(7):1665–1671. doi: 10.1093/annonc/mdr603, mdr603 [pii]PubMedCrossRefGoogle Scholar
  8. Esser KA, Harpole CE, Prins GS, Diamond AM (2009) Physical activity reduces prostate carcinogenesis in a transgenic model. Prostate 69(13):1372–1377. doi: 10.1002/pros.20987 PubMedCentralPubMedCrossRefGoogle Scholar
  9. Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, Terris MK (2006) Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 175 (2):500–504, discussion 504. doi:  10.1016/S0022-5347(05)00162-X, S0022-5347(05)00162-X [pii]Google Scholar
  10. Geybels MS, Neuhouser ML, Stanford JL (2013) Associations of tea and coffee consumption with prostate cancer risk. Cancer Causes Control. doi: 10.1007/s10552-013-0170-8 PubMedCentralGoogle Scholar
  11. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC (1997) Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 6(8):557–563PubMedGoogle Scholar
  12. Grubb RL 3rd, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, Riley TL, Ragard LR, Prorok PC, Berg CD, Crawford ED, Church TR, Andriole GL Jr (2009) Serum prostate-specific antigen hemodilution among obese men undergoing screening in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 18(3):748–751. doi: 10.1158/1055-9965.EPI-08-0938, 1055-9965.EPI-08-0938 [pii]PubMedCrossRefGoogle Scholar
  13. Hammarsten J, Hogstedt B (2005) Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 41(18):2887–2895. doi: 10.1016/j.ejca.2005.09.003, S0959-8049(05)00765-3 [pii]PubMedCrossRefGoogle Scholar
  14. Hoffman MA, DeWolf WC, Morgentaler A (2000) Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163(3):824–827. doi: S0022-5347(05)67812-3 PubMedCrossRefGoogle Scholar
  15. Hsing AW, Sakoda LC, Chua S Jr (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86(3):s843–857PubMedGoogle Scholar
  16. Imatoh T, Tanihara S, Miyazaki M, Momose Y, Uryu Y, Une H (2011) Coffee consumption but not green tea consumption is associated with adiponectin levels in Japanese males. Eur J Nutr 50(4):279–284. doi: 10.1007/s00394-010-0136-5 PubMedCrossRefGoogle Scholar
  17. Joshu CE, Mondul AM, Menke A, Meinhold C, Han M, Humphreys EB, Freedland SJ, Walsh PC, Platz EA (2011) Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. Cancer Prev Res (Phila) 4(4):544–551. doi: 10.1158/1940-6207.CAPR-10-0257, 1940-6207.CAPR-10-0257 [pii]CrossRefGoogle Scholar
  18. Kempf K, Herder C, Erlund I, Kolb H, Martin S, Carstensen M, Koenig W, Sundvall J, Bidel S, Kuha S, Tuomilehto J (2010) Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am J Clin Nutr 91(4):950–957. doi: 10.3945/ajcn.2009.28548, ajcn.2009.28548 [pii]PubMedCrossRefGoogle Scholar
  19. Kirsh VA, Peters U, Mayne ST, Subar AF, Chatterjee N, Johnson CC, Hayes RB (2007) Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst 99(15):1200–1209. doi: 10.1093/jnci/djm065, djm065 [pii]PubMedCrossRefGoogle Scholar
  20. Lee AH, Binns CW (2011) Re: coffee consumption and prostate cancer risk and progression in the health professionals follow-up study. J Natl Cancer Inst 103 (19):1481; author reply 1481–1482. doi:  10.1093/jnci/djr305, djr305 [pii]
  21. Lima N, Cavaliere H, Knobel M, Halpern A, Medeiros-Neto G (2000) Decreased androgen levels in massively obese men may be associated with impaired function of the gonadostat. Int J Obes Relat Metab Disord 24(11):1433–1437PubMedCrossRefGoogle Scholar
  22. Littman AJ, White E, Kristal AR (2007) Anthropometrics and prostate cancer risk. Am J Epidemiol 165(11):1271–1279. doi: 10.1093/aje/kwm013, kwm013 [pii]PubMedCrossRefGoogle Scholar
  23. Liu Y, Hu F, Li D, Wang F, Zhu L, Chen W, Ge J, An R, Zhao Y (2011) Does physical activity reduce the risk of prostate cancer? a systematic review and meta-analysis. Eur Urol 60(5):1029–1044. doi: 10.1016/j.eururo.2011.07.007, S0302-2838(11)00744-5 [pii]PubMedCrossRefGoogle Scholar
  24. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9(11):1039–1047. doi: 10.1016/S1470-2045(08)70235-3, S1470-2045(08)70235-3 [pii]PubMedCentralPubMedCrossRefGoogle Scholar
  25. Masko EM, Allott EH, Freedland SJ (2013) The relationship between nutrition and prostate cancer: is more always better? Eur Urol 63(5):810–820. doi: 10.1016/j.eururo.2012.11.012, S0302-2838(12)01343-7 [pii]PubMedCrossRefGoogle Scholar
  26. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T (2003) Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169(5):1670–1675. doi: 10.1097/01.ju.0000062674.43964.d0, S0022-5347(05)63642-7 [pii]PubMedCrossRefGoogle Scholar
  27. Moore SC, Patel AV, Matthews CE, de Gonzalez AB, Park Y, Katki HA, Linet MS, Weiderpass E, Visvanathan K, Helzlsouer KJ, Thun M, Gapstur SM, Hartge P, Lee IM (2012) Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis. PLoS Med 9(11):e1001335. doi: 10.1371/journal.pmed.1001335, PMEDICINE-D-12-00949 [pii]PubMedCentralPubMedCrossRefGoogle Scholar
  28. Nakajima A, Endo H, Yoneda K, Fujisawa T, Sugiyama M, Hosono K, Nozaki Y, Takahashi H, Fujita K, Yoneda M, Inamori M, Shimamura T, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Wada K, Nagakama H (2010) Molecular mechanisms linking adiponectin receptor signalling and cancer. Open Obes J 2(1):43–49CrossRefGoogle Scholar
  29. Park CH, Myung SK, Kim TY, Seo HG, Jeon YJ, Kim Y (2010) Coffee consumption and risk of prostate cancer: a meta-analysis of epidemiological studies. BJU Int 106(6):762–769. doi: 10.1111/j.1464-410X.2010.09493.x, BJU9493 [pii]PubMedCrossRefGoogle Scholar
  30. Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC, Giovannucci E (2005) Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 14(5):1262–1269. doi: 10.1158/1055-9965.EPI-04-0371, 14/5/1262 [pii]PubMedCrossRefGoogle Scholar
  31. Price MM, Hamilton RJ, Robertson CN, Butts MC, Freedland SJ (2008) Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology 71(5):787–791. doi: 10.1016/j.urology.2007.11.036, S0090-4295(07)02407-7 [pii]PubMedCrossRefGoogle Scholar
  32. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578. doi: 10.1016/S0140-6736(08)60269-X, S0140-6736(08)60269-X [pii]PubMedCrossRefGoogle Scholar
  33. Robinson WR, Stevens J, Gammon MD, John EM (2005) Obesity before age 30 years and risk of advanced prostate cancer. Am J Epidemiol 161(12):1107–1114. doi: 10.1093/aje/kwi150, 161/12/1107 [pii]PubMedCrossRefGoogle Scholar
  34. Roddam AW, Allen NE, Appleby P, Key TJ (2008a) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 100(3):170–183. doi: 10.1093/jnci/djm323, djm323 [pii]PubMedCrossRefGoogle Scholar
  35. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV, Jr., Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schroder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP, Jr., Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P (2008b) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149 (7):461–471, W483-468. doi:  149/7/461, [pii]
  36. Samitz G, Egger M, Zwahlen M (2011) Domains of physical activity and all-cause mortality: systematic review and dose-response meta-analysis of cohort studies. Int J Epidemiol 40(5):1382–1400. doi: 10.1093/ije/dyr112, dyr112 [pii]PubMedCrossRefGoogle Scholar
  37. Schatzl G, Madersbacher S, Thurridl T, Waldmuller J, Kramer G, Haitel A, Marberger M (2001) High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47(1):52–58. doi: 10.1002/pros.1046 PubMedCrossRefGoogle Scholar
  38. Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA (2000) Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol 151(6):541–549PubMedCrossRefGoogle Scholar
  39. Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P, Giles GG (2006) Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(1):86–91. doi: 10.1158/1055-9965.EPI-05-0633, 15/1/86 [pii]PubMedCrossRefGoogle Scholar
  40. Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS (2012) Coffee consumption and prostate cancer risk: further evidence for inverse relationship. Nutr J 11:42. doi: 10.1186/1475-2891-11-42, 1475-2891-11-42 [pii]PubMedCentralPubMedCrossRefGoogle Scholar
  41. Wedick NM, Brennan AM, Sun Q, Hu FB, Mantzoros CS, van Dam RM (2011) Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial. Nutr J 10:93. doi: 10.1186/1475-2891-10-93, 1475-2891-10-93 [pii]PubMedCentralPubMedCrossRefGoogle Scholar
  42. Whitley BM, Moreira DM, Thomas JA, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL, Freedland SJ (2011) Preoperative weight change and risk of adverse outcome following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. Prostate Cancer Prostatic Dis 14(4):361–366. doi: 10.1038/pcan.2011.42, pcan201142 [pii]PubMedCrossRefGoogle Scholar
  43. Williams CJ, Fargnoli JL, Hwang JJ, van Dam RM, Blackburn GL, Hu FB, Mantzoros CS (2008) Coffee consumption is associated with higher plasma adiponectin concentrations in women with or without type 2 diabetes: a prospective cohort study. Diabetes Care 31(3):504–507. doi: 10.2337/dc07-1952, dc07-1952 [pii]PubMedCentralPubMedCrossRefGoogle Scholar
  44. Wilson KM, Kasperzyk JL, Rider JR, Kenfield S, van Dam RM, Stampfer MJ, Giovannucci E, Mucci LA (2011) Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst 103(11):876–884. doi: 10.1093/jnci/djr151, djr151 [pii]PubMedCrossRefGoogle Scholar
  45. Woodcock J, Franco OH, Orsini N, Roberts I (2011) Non-vigorous physical activity and all-cause mortality: systematic review and meta-analysis of cohort studies. Int J Epidemiol 40(1):121–138. doi: 10.1093/ije/dyq104, dyq104 [pii]PubMedCrossRefGoogle Scholar
  46. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, Hurwitz P, Hollenbeck A, Leitzmann MF (2007) Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109(4):675–684. doi: 10.1002/cncr.22443 PubMedCrossRefGoogle Scholar
  47. Yasui T, Tomita J, Miyatani Y, Yamada M, Uemura H, Irahara M, Arai M, Kojimahara N, Okabe R, Ishii Y, Tashiro S, Sato H (2007) Associations of adiponectin with sex hormone-binding globulin levels in aging male and female populations. Clin Chim Acta 386(1–2):69–75. doi: 10.1016/j.cca.2007.08.001, S0009-8981(07)00393-2 [pii]PubMedCrossRefGoogle Scholar
  48. Yu X, Bao Z, Zou J, Dong J (2011) Coffee consumption and risk of cancers: a meta-analysis of cohort studies. BMC Cancer 11:96. doi: 10.1186/1471-2407-11-96, 1471-2407-11-96 [pii]PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Unit of Nutritional Epidemiology, Division of EpidemiologyInstitute of Environmental Medicine, Karolinska InstitutetStockholmSweden

Personalised recommendations